随着介入治疗、CT和三维重建新技术的发展及血管内造影剂的使用，对比剂肾损伤（CI-AKI）的发生率显著上升。早期诊断CI-AKI可及时治疗并显著改善患者的预后。然而，血清肌酐（SCr）作为急性肾损伤（AKI）的诊断标志物却有着延后性与不可靠性。随着研究的进展，胱抑素C（CysC）生物标志物引起了人们广泛关注，为CI-AKI的早期诊断，甚至为预测主要心血管不良事件（MACE）的发生提供了可能。该文对近年来相关CysC作为早期诊断CI-AKI的标志物及预测MACE的研究作一综述，探讨CysC的应用可能及前景。

With the development of intervention therapy, CT, and three dimension reconstruction technology and the application of intravascular contrast media, the incidence of contrast-induced acute kidney injury (CI-AKI) increased rapidly. Early diagnosis of CI-AKI contributes to timely treatment and significantly improves the prognosis. However, it is lagging and unreliable to use serum creatine (SCr) as a biomarker for the diagnosis of acute kidney injury (AKI). With the development of research, much attention has been paid to the biomarker of cystatin C (CysC), which seems to provide the possibility for the early diagnosis of CI-AKI and predicting the incidence of major adverse cardiac events (MACE). This paper reviews recent researches relevant to using CysC as the biomarker for early diagnosis of CI-AKI and prediction of MACE and discusses the possibility and prospect of application of CysC.